EGFR and non-small cell lung carcinoma: Although no BRAF inhibitor has yet been granted approval for patients with BRAF V600E-mutant NSCLC by the CFDA, a second-generation BRAF inhibitor named BGB-283 developed in China has displayed potent inhibition in preclinical studies on BRAFV600E and EGFR mutation/amplification.